We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of figitumumab in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: clinical activity and molecular response (GORTEC 2008-02).
- Authors
Schmitz, S; Kaminsky-Forrett, M-C; Henry, S; Zanetta, S; Geoffrois, L; Bompas, E; Moxhon, A; Mignion, L; Guigay, J; Knoops, L; Hamoir, M; Machiels, J-P
- Abstract
Preclinical studies suggest that insulin-like growth factor-1 receptor (IGF-1R) blockage could be a promising therapeutic target in squamous cell carcinoma of the head and neck (SCCHN). Therefore, we investigated the efficacy and toxicity of figitumumab, an anti-IGF-1R monoclonal antibody, in palliative SCCHN.
- Publication
Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Vol 23, Issue 8, p2153
- ISSN
1569-8041
- Publication type
Journal Article
- DOI
10.1093/annonc/mdr574